Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study

A. M. Pellicelli; V. Pace Palitti; P. Vignally; F. Ceccherini-Silberstein; M. Siciliano; V. Giannelli; A. Moretti; P. Tarquini; G. Scifo; V. Messina; A. Ascione; A. Izzi; M. Marignani; C. D'Ambrosio; L. Fondacaro; G. M. Ettorre; P. Ialongo; R. Sacco; C. F. Perno; G. Barbarini; CLEO Group

doi:10.1111/liv.13288 [doi]

Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study

A. M. Pellicelli, V. Pace Palitti, P. Vignally, F. Ceccherini-Silberstein, M. Siciliano, V. Giannelli, A. Moretti, P. Tarquini, G. Scifo, V. Messina, A. Ascione, A. Izzi, M. Marignani, C. D'Ambrosio, L. Fondacaro, G. M. Ettorre, P. Ialongo, R. Sacco, C. F. Perno, G. BarbariniCLEO Group

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND & AIMS: The proportion of HCV-infected patients over age 65 years in Western countries is increasing. This growth and the advent of new antiviral therapy bring into the question the real-world efficacy and safety of the combination of sofosbuvir (SOF) and simeprevir (SMV) plus a flat dose of 800 mg/d ribavirin (RBV) in elderly patients with cirrhosis compared to younger patients. METHODS: Retrospective observational multicentre real-life investigation study of SOF/SMV/RBV for a duration of 12 weeks in HCV genotype 1-infected patients with cirrhosis. RESULTS: Of the 270 patients enrolled in this study, with compensated cirrhosis, 133 (49.2%) were >/=65 years of age. Sustained virological response at 12 weeks (SVR12) was achieved by 94.2% (129/137) of those aged /=65 years. Diabetes was the most common comorbidity in patients >/=65 years compared to younger patients (26.3% vs 12.4% P

Original language	English
Pages (from-to)	653-661
Number of pages	9
Journal	Liver International
Volume	37
Issue number	5
DOIs	https://doi.org/10.1111/liv.13288 [doi]
Publication status	Published - May 1 2017

Keywords

cirrhosis
elderly
genotype 1
hepatitis C
simeprevir
sofosbuvir

Access to Document

10.1111/liv.13288 [doi]

Fingerprint Dive into the research topics of 'Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study'. Together they form a unique fingerprint.

Cite this

Pellicelli, A. M., Palitti, V. P., Vignally, P., Ceccherini-Silberstein, F., Siciliano, M., Giannelli, V., Moretti, A., Tarquini, P., Scifo, G., Messina, V., Ascione, A., Izzi, A., Marignani, M., D'Ambrosio, C., Fondacaro, L., Ettorre, G. M., Ialongo, P., Sacco, R., Perno, C. F., ... Group, CLEO. (2017). Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study. Liver International, 37(5), 653-661. https://doi.org/10.1111/liv.13288 [doi]

Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study. / Pellicelli, A. M.; Palitti, V. Pace; Vignally, P.; Ceccherini-Silberstein, F.; Siciliano, M.; Giannelli, V.; Moretti, A.; Tarquini, P.; Scifo, G.; Messina, V.; Ascione, A.; Izzi, A.; Marignani, M.; D'Ambrosio, C.; Fondacaro, L.; Ettorre, G. M.; Ialongo, P.; Sacco, R.; Perno, C. F.; Barbarini, G.; Group, CLEO.

In: Liver International, Vol. 37, No. 5, 01.05.2017, p. 653-661.

Research output: Contribution to journal › Article › peer-review

Pellicelli, AM, Palitti, VP, Vignally, P, Ceccherini-Silberstein, F, Siciliano, M, Giannelli, V, Moretti, A, Tarquini, P, Scifo, G, Messina, V, Ascione, A, Izzi, A, Marignani, M, D'Ambrosio, C, Fondacaro, L, Ettorre, GM, Ialongo, P, Sacco, R , Perno, CF, Barbarini, G & Group, CLEO 2017, 'Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study', Liver International, vol. 37, no. 5, pp. 653-661. https://doi.org/10.1111/liv.13288 [doi]

Pellicelli, A. M. ; Palitti, V. Pace ; Vignally, P. ; Ceccherini-Silberstein, F. ; Siciliano, M. ; Giannelli, V. ; Moretti, A. ; Tarquini, P. ; Scifo, G. ; Messina, V. ; Ascione, A. ; Izzi, A. ; Marignani, M. ; D'Ambrosio, C. ; Fondacaro, L. ; Ettorre, G. M. ; Ialongo, P. ; Sacco, R. ; Perno, C. F. ; Barbarini, G. ; Group, CLEO. / Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study. In: Liver International. 2017 ; Vol. 37, No. 5. pp. 653-661.

@article{7e079a2a38824b60973bebe247ae3871,

title = "Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study",

abstract = "BACKGROUND & AIMS: The proportion of HCV-infected patients over age 65 years in Western countries is increasing. This growth and the advent of new antiviral therapy bring into the question the real-world efficacy and safety of the combination of sofosbuvir (SOF) and simeprevir (SMV) plus a flat dose of 800 mg/d ribavirin (RBV) in elderly patients with cirrhosis compared to younger patients. METHODS: Retrospective observational multicentre real-life investigation study of SOF/SMV/RBV for a duration of 12 weeks in HCV genotype 1-infected patients with cirrhosis. RESULTS: Of the 270 patients enrolled in this study, with compensated cirrhosis, 133 (49.2%) were >/=65 years of age. Sustained virological response at 12 weeks (SVR12) was achieved by 94.2% (129/137) of those aged /=65 years. Diabetes was the most common comorbidity in patients >/=65 years compared to younger patients (26.3% vs 12.4% P",

keywords = "cirrhosis, elderly, genotype 1, hepatitis C, simeprevir, sofosbuvir",

author = "Pellicelli, {A. M.} and Palitti, {V. Pace} and P. Vignally and F. Ceccherini-Silberstein and M. Siciliano and V. Giannelli and A. Moretti and P. Tarquini and G. Scifo and V. Messina and A. Ascione and A. Izzi and M. Marignani and C. D'Ambrosio and L. Fondacaro and Ettorre, {G. M.} and P. Ialongo and R. Sacco and Perno, {C. F.} and G. Barbarini and CLEO Group",

note = "LR: 20170428; CI: (c) 2016; JID: 101160857; OTO: NOTNLM; 2016/03/24 00:00 [received]; 2016/10/21 00:00 [accepted]; 2016/10/27 06:00 [pubmed]; 2016/10/27 06:00 [medline]; 2016/10/27 06:00 [entrez]; ppublish",

year = "2017",

month = may,

day = "1",

doi = "10.1111/liv.13288 [doi]",

language = "English",

volume = "37",

pages = "653--661",

journal = "Liver International",

issn = "1478-3223",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "5",

}

TY - JOUR

T1 - Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study

AU - Pellicelli, A. M.

AU - Palitti, V. Pace

AU - Vignally, P.

AU - Ceccherini-Silberstein, F.

AU - Siciliano, M.

AU - Giannelli, V.

AU - Moretti, A.

AU - Tarquini, P.

AU - Scifo, G.

AU - Messina, V.

AU - Ascione, A.

AU - Izzi, A.

AU - Marignani, M.

AU - D'Ambrosio, C.

AU - Fondacaro, L.

AU - Ettorre, G. M.

AU - Ialongo, P.

AU - Sacco, R.

AU - Perno, C. F.

AU - Barbarini, G.

AU - Group, CLEO

N1 - LR: 20170428; CI: (c) 2016; JID: 101160857; OTO: NOTNLM; 2016/03/24 00:00 [received]; 2016/10/21 00:00 [accepted]; 2016/10/27 06:00 [pubmed]; 2016/10/27 06:00 [medline]; 2016/10/27 06:00 [entrez]; ppublish

PY - 2017/5/1

Y1 - 2017/5/1

N2 - BACKGROUND & AIMS: The proportion of HCV-infected patients over age 65 years in Western countries is increasing. This growth and the advent of new antiviral therapy bring into the question the real-world efficacy and safety of the combination of sofosbuvir (SOF) and simeprevir (SMV) plus a flat dose of 800 mg/d ribavirin (RBV) in elderly patients with cirrhosis compared to younger patients. METHODS: Retrospective observational multicentre real-life investigation study of SOF/SMV/RBV for a duration of 12 weeks in HCV genotype 1-infected patients with cirrhosis. RESULTS: Of the 270 patients enrolled in this study, with compensated cirrhosis, 133 (49.2%) were >/=65 years of age. Sustained virological response at 12 weeks (SVR12) was achieved by 94.2% (129/137) of those aged /=65 years. Diabetes was the most common comorbidity in patients >/=65 years compared to younger patients (26.3% vs 12.4% P

AB - BACKGROUND & AIMS: The proportion of HCV-infected patients over age 65 years in Western countries is increasing. This growth and the advent of new antiviral therapy bring into the question the real-world efficacy and safety of the combination of sofosbuvir (SOF) and simeprevir (SMV) plus a flat dose of 800 mg/d ribavirin (RBV) in elderly patients with cirrhosis compared to younger patients. METHODS: Retrospective observational multicentre real-life investigation study of SOF/SMV/RBV for a duration of 12 weeks in HCV genotype 1-infected patients with cirrhosis. RESULTS: Of the 270 patients enrolled in this study, with compensated cirrhosis, 133 (49.2%) were >/=65 years of age. Sustained virological response at 12 weeks (SVR12) was achieved by 94.2% (129/137) of those aged /=65 years. Diabetes was the most common comorbidity in patients >/=65 years compared to younger patients (26.3% vs 12.4% P

KW - cirrhosis

KW - elderly

KW - genotype 1

KW - hepatitis C

KW - simeprevir

KW - sofosbuvir

U2 - 10.1111/liv.13288 [doi]

DO - 10.1111/liv.13288 [doi]

M3 - Article

VL - 37

SP - 653

EP - 661

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 5

ER -